Latent CMV in Pregnant Women: Dangerous Even without Transmission to the Baby; polyDNA Recommends Targeting the Latent Cytomegalovirus with Gene-Eden-VIR

A congenital (existing before and during birth) infection with the cytomegalovirus (HCMV or CMV) is associated with intrauterine growth restriction (IUGR), a condition that can be life threatening to babies, according to a study published on January 7, 2014 in the Journal of Infectious Diseases (1). polyDNA recommends that women speak to their doctors about Gene-Eden-VIR when planning a pregnancy.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
We recommend targeting the latent CMV prior to getting pregnant. Before a woman attempts to conceive, she should speak with her doctor about taking Gene-Eden-VIR. - Mike Evans, polyDNA

Rochester, NY (PRWEB) March 29, 2014

The cytomegalovirus (CMV) is the virus that causes the most birth defects and deaths in infants (1). Now a new study has found that the virus can harm, and possibly kill, a baby even if only the mother is infected. It does this by causing a condition in the mother’s womb called intrauterine growth restriction (IUGR). “Congenital HCMV infection impairs placental development and functions and should be considered as an underlying cause of IUGR, regardless of virus transmission to the fetus (1).” polyDNA recommends that parents planning a pregnancy speak to their doctors about Gene-Eden-VIR. This natural antiviral targets the latent CMV, and was recently proven to reduce symptoms of a CMV infection in a post-marketing clinical study that followed FDA guidelines.

Women planning a pregnancy should understand that “Infants with IUGR, birth weights less than 10th percentile, have a perinatal morbidity and mortality (disease and death around the time of birth) 5 to 30 times that of infants with higher weights (1).” In addition, congenital CMV infection “occurs more frequently than other well-known disabilities, including Down syndrome, fetal alcohol syndrome and neural tube defects. Primary maternal infection in the first trimester of pregnancy poses a 30%-40% risk of virus transmission with birth defects that include mental retardation, neuromotor disabilities, intrauterine growth restriction (IUGR) and hearing loss (1).”

“For pregnant women, the most common exposures to CMV are through contact with the saliva and urine of young children or through sexual contact. Young children can transmit CMV for months after they first become infected. However, CMV does not spread easily. One in 5 parents of children who have active CMV infections become infected with CMV over the course of a year.” (See the CDC’s website, last updated on June 24, 2013) (2).

“In the United States, more than 5,000 children suffer illness and permanent disabilities caused by congenital CMV infection every year (2).”

For many years, it was thought that children born to mothers with an active CMV infection were at the highest risk. However, recent studies have shown that even when the mother has a latent CMV infection, the risk to the newborn is also high. Researchers wrote that “symptomatic infection occurs with similar frequency in children born to women with primary CMV infection and those born to women who were CMV seroimmune (that is, the mother has a latent CMV infection) before pregnancy. In addition, the severity of newborn disease and the rates of CMV-associated SNHL (the viral protein) also do not differ between primary and nonprimary (latent) infection groups.” (See Clinical Infectious Diseases, from December 2013) (3).

What can parents do to reduce the risk of CMV infection?

There are some drugs approved for use against a CMV infection. However, most of these are used exclusively in immunocompromised individuals (such as those with HIV). In healthy people these drugs are “limited by their toxicity, poor oral bioavailability, modest efficacy, and the development of drug resistance.” (See Pharmacology & Pharmacy, from September 2013) (4).

There are also some natural remedies available. However, only Gene-Eden-VIR has undergone rigorous scientific testing. In a post marketing clinical study published on August 12, 2013 in the medical journal Pharmacology & Pharmacy in a special edition on Advances in Antiviral Drugs, researchers showed that Gene-Eden-VIR is safe and effective (4). Additionally, up to 70% of those studied reported a decrease in symptoms associated with EBV infection, and users experienced an increase in overall health (4).

Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target latent viruses (4).

“We recommend targeting the latent CMV prior to getting pregnant. Before a woman attempts to conceive, she should speak with her doctor about taking Gene-Eden-VIR. As the study authors wrote, 'Healthcare practitioners should recommend Gene-Eden-VIR as a safe and effective antiviral treatment.'” -Mike Evans, polyDNA

Additionally, CMV can cause a pregnant woman to feel fatigued. A second clinical study showed that Gene-Eden-VIR decreased physical and mental fatigue. (See Pharmacology & Pharmacy, from March, 2014) (5).

polyDNA recommends that women who take Gene-Eden-VIR stop taking it before getting pregnant, and start taking again after the delivery of the baby.

To learn more about Gene-Eden-VIR, visit http://www.gene-eden-vir.com.

All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Intrauterine growth restriction caused by underlying congenital cytomegalovirus
infection. Published on January 7, 2014.
http://jid.oxfordjournals.org/content/early/2014/01/07/infdis.jiu019.full.pdf+html

(2) CDC - Cytomegalovirus: Protect Your Baby. Last updated on June 24, 2013.
http://www.cdc.gov/features/cytomegalovirus/

(3) Congenital cytomegalovirus infection: clinical outcome. Published December 2013.
http://www.ncbi.nlm.nih.gov/pubmed/24257422

(4) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.UzUrbKiSz90

(5) Gene-Eden-VIR Decreased Physical and Mental Fatigue in a Post Marketing Clinical Study That Followed FDA Guidelines; Results Support Microcompetition Theory. Published in March 2014.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234#.UzUrmaiSz90

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.